Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
17 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250717410973/en/Aldeyra-Therapeutics-Announces-FDA-Acceptance-for-Review-of-Reproxalap-New-Drug-Application-for-the-Treatment-of-Dry-Eye-Disease
26 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250626651175/en/Aldeyra-Therapeutics-Receives-Special-Protocol-Assessment-Agreement-Letter-from-the-U.S.-Food-and-Drug-Administration-for-ADX-2191-for-the-Treatment-of-Primary-Vitreoretinal-Lymphoma
17 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250617568242/en/Aldeyra-Therapeutics-Resubmits-Reproxalap-New-Drug-Application-for-the-Treatment-of-Dry-Eye-Disease
29 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250529740806/en/Aldeyra-Therapeutics-to-Participate-in-the-2025-Jefferies-Global-Healthcare-Conference
05 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250506374075/en/Aldeyra-Therapeutics-Achieves-Primary-Endpoint-in-Phase-3-Dry-Eye-Disease-Chamber-Trial-of-Reproxalap-and-Plans-NDA-Resubmission
05 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250505228210/en/Aldeyra-Therapeutics-Schedules-Conference-Call-and-Webcast-to-Announce-Topline-Results-from-Phase-3-Dry-Eye-Disease-Clinical-Trials-of-Reproxalap
ABOUT THIS PAGE